| المنتج | التاريخ | معلومات السلامة | المرفقات |
|---|---|---|---|
| Levofloxacin Sandoz (Levofloxacin) | 2020-09-13 | Systemic fluoroquinolones: risk of heart valve regurgitation |
|
| Curacne (Isotretinoin) | 2020-08-19 | Isotretinoin - update on teratogenicity and neuropsychiatric disorders |
|
| Verorab (Rabies Vaccine, Inactivated) | 2020-07-19 | Updated information on the reconstitution and administration of rabies vaccine, inactivated (VERORAB) |
|
| Megamox (Amoxicillin / Clavulanic acid) | 2020-05-06 | Megamox® 625mg tablets is associated with a typographic error in the units for the weight of the product stated on the aluminum foil. |
|
| Esbriet® (Pirfenidone) | 2019-12-08 | Important Safety Update on ESBRIET® (pirfenidone) and Drug-Induced Liver Injury (DILI) |
|
| Advaquin ( levofloxacin) | 2019-08-13 | Advaquin ( levofloxacin): Risk of aortic aneurysm and dissection. |
|
| Apixaban, Edoxaban, Dabigatran and Rivaroxaban | 2019-06-12 | Direct Healthcare Professional Communication (DHPC) for the Direct Oral Anticoagulants (DOACs) Apixaban, Edoxaban, Dabigatran and Rivaroxaban. |
|
| blinatumomab | 2019-05-07 | Blincyto (pembrolizumab): Risk of Medication Errors and Benzyl alcohol toxicity. |
|
| Jectin-12® (Cyanocobalamin) | 2019-05-06 | Cyanocobalamin and the risk of medication error. |
|
| Genvoya ® (elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide) | 2019-04-29 | Increased risk of treatment failure and increased risk of mother-to-child transmission of HIV infection due to lower exposure of elvitegravir and cobicistat during the second and third trimesters of pregnancy. |